Haley Gittleman

9PUBLICATIONS
64CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiologyFlight dynamicsPharmaceutical delivery technologiesGenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

Suparna Wedam, Preeti Narayan, Haley Gittleman

|Aug 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.

Jennifer J Gao, Tatiana M Prowell, Haley Gittleman

|Feb 28, 2024
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.

Elaine Chang, Jiaxi Zhou, Chi Song

|Feb 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.

Mirat Shah, Hima Lingam, Xin Gao

|May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.

Asma Dilawari, Mirat Shah, Gwynn Ison

|Dec 05, 2022
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.

Jaleh Fallah, Sundeep Agrawal, Haley Gittleman

Pageof 2

Frequent Collaborators

6 joint publications

Richard Pazdur

6 joint publications

Shenghui Tang

6 joint publications

Laleh Amiri-Kordestani

5 joint publications

William Pierce